FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007217713> ?p ?o ?g. }

• W2007217713 endingPage "1737" @default.
• W2007217713 startingPage "1733" @default.
• W2007217713 abstract "BACKGROUND: The hepatitis C virus (HCV) genotype is an important predictive parameter for the success of pegylated interferon plus ribavirin therapy. To date, most published therapeutic trials have enrolled patients infected mainly with HCV genotypes 1, 2, and 3. Data regarding the responsiveness of genotype 4, the predominant type of HCV in the Middle East, are very limited. OBJECTIVE: To assess the efficacy of peginterferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis caused by HCV genotype 4. METHODS: Sixty-six treatment-naive patients infected with HCV genotype 4 were enrolled in this open label, prospective study. Cohort characteristics included the following: 48 M/18 F, mean age 45 ± 9 years, and mean weight 74 ± 8 kg. All patients had raised alanine aminotransferase (ALT) and were compensated. The mean pretreatment HCV-RNA level was 4.2 × 106 copies/ml (8.4 × 105 iu/ml) and median was 2.15 × 106 copies/ml. Twenty patients (29%) exhibited cirrhosis or severe fibrosis on pretreatment liver biopsy specimens. Participants were to receive peginterferon alfa-2b, 1.5 mcg/kg/wk plus ribavirin 1,000–1,200 mg/day for 48 wk. Patients were followed up for 24 wk after completing therapy. End of treatment viral response and sustained viral response (SVR) were defined as the absence of HCV-RNA from serum (<100 copies/ml) at 48 wk of treatment and at the end of follow-up, respectively. Data were analyzed on an intention-to-treat basis. RESULTS: End of treatment and sustained virologic response were 77% and 68%, respectively. Among patients with pretreatment HCV-RNA ≥2 × 106 SVR was 55% compared with SVR of 86% among patients with HCV-RNA < 2 × 106 (p= 0.05). Patients with cirrhosis or severe fibrosis had significantly lower SVR rate compared to those with mild or no fibrosis (29 vs 84%; p < 0.0002). Three patients (4%) discontinued therapy because of severe flu-like symptoms. Four patients developed hypothyroidism. Dose reduction of ribavirin and peginterferon alfa-2b was necessary in 15% and 6% of the patients, respectively. CONCLUSION: Peginterferon alfa-2b in combination with ribavirin is effective in the treatment of HCV genotype 4. The treatment was well tolerated by most of the patients. (Am J Gastroenterol 2004;99:1733-1737)" @default.
• W2007217713 created "2016-06-24" @default.
• W2007217713 creator A5006729552 @default.
• W2007217713 creator A5010623508 @default.
• W2007217713 creator A5021881389 @default.
• W2007217713 creator A5039456908 @default.
• W2007217713 creator A5042744224 @default.
• W2007217713 creator A5054850325 @default.
• W2007217713 creator A5065568469 @default.
• W2007217713 creator A5072253670 @default.
• W2007217713 date "2004-09-01" @default.
• W2007217713 modified "2023-10-07" @default.
• W2007217713 title "Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4" @default.
• W2007217713 cites W1975947881 @default.
• W2007217713 cites W2014185629 @default.
• W2007217713 cites W2028850957 @default.
• W2007217713 cites W2114376411 @default.
• W2007217713 cites W2127685726 @default.
• W2007217713 cites W2160626977 @default.
• W2007217713 cites W2165715544 @default.
• W2007217713 cites W2167100006 @default.
• W2007217713 cites W2317554121 @default.
• W2007217713 cites W2762063323 @default.
• W2007217713 doi "https://doi.org/10.1111/j.1572-0241.2004.40077.x" @default.
• W2007217713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15330911" @default.
• W2007217713 hasPublicationYear "2004" @default.
• W2007217713 type Work @default.
• W2007217713 sameAs 2007217713 @default.
• W2007217713 citedByCount "110" @default.
• W2007217713 countsByYear W20072177132012 @default.
• W2007217713 countsByYear W20072177132013 @default.
• W2007217713 countsByYear W20072177132014 @default.
• W2007217713 countsByYear W20072177132015 @default.
• W2007217713 countsByYear W20072177132016 @default.
• W2007217713 countsByYear W20072177132017 @default.
• W2007217713 countsByYear W20072177132018 @default.
• W2007217713 crossrefType "journal-article" @default.
• W2007217713 hasAuthorship W2007217713A5006729552 @default.
• W2007217713 hasAuthorship W2007217713A5010623508 @default.
• W2007217713 hasAuthorship W2007217713A5021881389 @default.
• W2007217713 hasAuthorship W2007217713A5039456908 @default.
• W2007217713 hasAuthorship W2007217713A5042744224 @default.
• W2007217713 hasAuthorship W2007217713A5054850325 @default.
• W2007217713 hasAuthorship W2007217713A5065568469 @default.
• W2007217713 hasAuthorship W2007217713A5072253670 @default.
• W2007217713 hasConcept C104317684 @default.
• W2007217713 hasConcept C126322002 @default.
• W2007217713 hasConcept C135763542 @default.
• W2007217713 hasConcept C142462285 @default.
• W2007217713 hasConcept C185592680 @default.
• W2007217713 hasConcept C203014093 @default.
• W2007217713 hasConcept C2522874641 @default.
• W2007217713 hasConcept C2776235749 @default.
• W2007217713 hasConcept C2776408679 @default.
• W2007217713 hasConcept C2776455275 @default.
• W2007217713 hasConcept C2776461080 @default.
• W2007217713 hasConcept C2777214474 @default.
• W2007217713 hasConcept C2778606649 @default.
• W2007217713 hasConcept C2780040827 @default.
• W2007217713 hasConcept C55493867 @default.
• W2007217713 hasConcept C71924100 @default.
• W2007217713 hasConcept C90924648 @default.
• W2007217713 hasConceptScore W2007217713C104317684 @default.
• W2007217713 hasConceptScore W2007217713C126322002 @default.
• W2007217713 hasConceptScore W2007217713C135763542 @default.
• W2007217713 hasConceptScore W2007217713C142462285 @default.
• W2007217713 hasConceptScore W2007217713C185592680 @default.
• W2007217713 hasConceptScore W2007217713C203014093 @default.
• W2007217713 hasConceptScore W2007217713C2522874641 @default.
• W2007217713 hasConceptScore W2007217713C2776235749 @default.
• W2007217713 hasConceptScore W2007217713C2776408679 @default.
• W2007217713 hasConceptScore W2007217713C2776455275 @default.
• W2007217713 hasConceptScore W2007217713C2776461080 @default.
• W2007217713 hasConceptScore W2007217713C2777214474 @default.
• W2007217713 hasConceptScore W2007217713C2778606649 @default.
• W2007217713 hasConceptScore W2007217713C2780040827 @default.
• W2007217713 hasConceptScore W2007217713C55493867 @default.
• W2007217713 hasConceptScore W2007217713C71924100 @default.
• W2007217713 hasConceptScore W2007217713C90924648 @default.
• W2007217713 hasIssue "9" @default.
• W2007217713 hasLocation W20072177131 @default.
• W2007217713 hasLocation W20072177132 @default.
• W2007217713 hasOpenAccess W2007217713 @default.
• W2007217713 hasPrimaryLocation W20072177131 @default.
• W2007217713 hasRelatedWork W2004479501 @default.
• W2007217713 hasRelatedWork W2009634266 @default.
• W2007217713 hasRelatedWork W2045556878 @default.
• W2007217713 hasRelatedWork W2067034737 @default.
• W2007217713 hasRelatedWork W2078888723 @default.
• W2007217713 hasRelatedWork W2108648362 @default.
• W2007217713 hasRelatedWork W2318824964 @default.
• W2007217713 hasRelatedWork W2321188506 @default.
• W2007217713 hasRelatedWork W2977427228 @default.
• W2007217713 hasRelatedWork W4229934245 @default.
• W2007217713 hasVolume "99" @default.
• W2007217713 isParatext "false" @default.
• W2007217713 isRetracted "false" @default.
• W2007217713 magId "2007217713" @default.

• next